1. P866: CORRELATIVE ANALYSIS TO DEFINE PATIENT PROFILES ASSOCIATED WITH MANUFACTURING AND CLINICAL ENDPOINTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL (BB2121). (23rd June 2022) Authors: Rytlewski, J.; Fuller, J.; Mertz, D. R.; Freeman, C.; Manier, S.; Shah, N.; Campbell, T. B. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 759 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P867: TUMOR PROFILING OF IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) PATIENTS IN KARMMA SHOWED COMPARABLE RESPONSES IN EXISTING MOLECULAR HIGH-RISK SUBSETS AND PRELIMINARY GENE SIGNATURE OF DURABLE RESPONSE. (23rd June 2022) Authors: Martin, N.; Xu, A.; Stong, N.; Rytlewski, J.; Finney, O.; Campbell, T.; Pierceall, W.; Flynt, E.; Thompson, E.; Kaiser, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗